Ads
related to: d phenylalanine side effects children s claritin liquid dosage
Search results
Results from the WOW.Com Content Network
D-Phenylalanine (DPA, D-Phe), sold under the brand names Deprenon, Sabiben, and Sabiden, is an enantiomer of phenylalanine which is described as an antidepressant and is marketed as a prescription drug for medical use in Argentina. [1] [2] The medication has been marketed since at least the 1970s [3] and continued to be available by the 2000s. [1]
D-Phenylalanine is distributed to the various tissues of the body via the systemic circulation. It appears to cross the blood–brain barrier less efficiently than L-phenylalanine, and so a small amount of an ingested dose of D-phenylalanine is excreted in the urine without penetrating the central nervous system. [24] L-Phenylalanine is an ...
Loratadine, sold under the brand name Claritin among others, is a medication used to treat allergies. [5] This includes allergic rhinitis (hay fever) and hives. [5] It is also available in drug combinations such as loratadine/pseudoephedrine, in which it is combined with pseudoephedrine, a nasal decongestant. [5]
Desloratadine sold under the brand name Clarinex among others, is a tricyclic H 1 inverse agonist that is used to treat allergies.It is an active metabolite of loratadine. [6]It was patented in 1984 and came into medical use in 2001. [7]
D-Phenylalanine is a psychostimulant and selective norepinephrine releasing agent (NRA) or norepinephrine-preferring norepinephrine–dopamine releasing agent (NDRA). [ 1 ] [ 2 ] The EC 50 Tooltip half-maximal effective concentration values of D -phenylalanine for monoamine release are 106 nM for norepinephrine, 1,355 nM for dopamine , and ...
Phenylpropanolamine was previously available in the United States over-the-counter and in certain combination drug forms by prescription. [24] [25] One such example of the latter was a combination of phenylpropanolamine and chlorpheniramine, which dually contained decongestant and antihistamine effects, marketed by Tutag as 'Vernate'.
The first ODT form of a drug to get approval from the U.S. Food and Drug Administration (FDA) was a Zydis ODT formation of Claritin in December 1996. [19] It was followed by a Zydis ODT formulation of Klonopin in December 1997, [20] and a Zydis ODT formulation of Maxalt (rizatriptan) in June 1998. [21]
A Clarinase Repetab tablet contains 5 mg loratadine in the tablet coating and 120 mg pseudoephedrine sulfate equally distributed between the tablet coating and the barrier-coated core.
Ads
related to: d phenylalanine side effects children s claritin liquid dosage